Literature DB >> 1380788

L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro.

M E Goldman1, J A O'Brien, T L Ruffing, J H Nunberg, W A Schleif, J C Quintero, P K Siegl, J M Hoffman, A M Smith, E A Emini.   

Abstract

L-696,229 (3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-pyridin-2 (1H)-one) is a specific inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) activity that possesses antiviral activity in cell culture (W.S. Saari, J.M. Hoffman, J.S. Wai, T.E. Fisher, C.S. Rooney, A.M. Smith, C.M. Thomas, M. E. Goldman, J. A. O'Brien, J. H. Nunberg, J. C. Quintero, W. A. Schleif, E. A. Emini, and P. S. Anderson, J. Med. Chem. 34:2922-2925, 1991). In the present study, the RT-inhibitory activity and antiviral properties were characterized in detail. The inhibition of RT activity was template-primer dependent with 50% inhibitory concentrations of 0.018 to 0.50 microM and was noncompetitive with respect to deoxynucleoside triphosphates. L-696,229 inhibited RT activity in a mutually exclusive manner with respect to either phosphonoformate or azidothymidine triphosphate and was a weak partial inhibitor of the RNase H activity associated with HIV-1 RT. The compound did not significantly inhibit other retroviral or cellular polymerases at 300 microM.L-696,229 inhibited the spread of HIV-1 infection in cell cultures with all cell types and viral isolates tested, including human peripheral blood mononuclear cells and a virus isolate resistant to azidothymidine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380788      PMCID: PMC188828          DOI: 10.1128/AAC.36.5.1019

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  STUDIES ON LIVER ALCOHOL HYDROGENASE COMPLEXES. 3. MULTIPLE INHIBITION KINETICS IN THE PRESENCE OF TWO COMPETITIVE INHIBITORS.

Authors:  T YONETANI; H THEORELL
Journal:  Arch Biochem Biophys       Date:  1964-07-20       Impact factor: 4.013

2.  A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates.

Authors:  E L White; R W Buckheit; L J Ross; J M Germany; K Andries; R Pauwels; P A Janssen; W M Shannon; M A Chirigos
Journal:  Antiviral Res       Date:  1991-10       Impact factor: 5.970

3.  2-Pyridinone derivatives: a new class of nonnucleoside, HIV-1-specific reverse transcriptase inhibitors.

Authors:  W S Saari; J M Hoffman; J S Wai; T E Fisher; C S Rooney; A M Smith; C M Thomas; M E Goldman; J A O'Brien; J H Nunberg
Journal:  J Med Chem       Date:  1991-09       Impact factor: 7.446

4.  Human immunodeficiency virus reverse transcriptase-associated RNase H activity.

Authors:  M C Starnes; Y C Cheng
Journal:  J Biol Chem       Date:  1989-04-25       Impact factor: 5.157

5.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

6.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.

Authors:  R Pauwels; K Andries; J Desmyter; D Schols; M J Kukla; H J Breslin; A Raeymaeckers; J Van Gelder; R Woestenborghs; J Heykants
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

7.  Inhibition of human immunodeficiency virus-1 reverse transcriptase activity by rubromycins: competitive interaction at the template.primer site.

Authors:  M E Goldman; G S Salituro; J A Bowen; J M Williamson; D L Zink; W A Schleif; E A Emini
Journal:  Mol Pharmacol       Date:  1990-07       Impact factor: 4.436

8.  Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template.

Authors:  E B Kopp; J J Miglietta; A G Shrutkowski; C K Shih; P M Grob; M T Skoog
Journal:  Nucleic Acids Res       Date:  1991-06-11       Impact factor: 16.971

9.  Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor.

Authors:  V J Merluzzi; K D Hargrave; M Labadia; K Grozinger; M Skoog; J C Wu; C K Shih; K Eckner; S Hattox; J Adams
Journal:  Science       Date:  1990-12-07       Impact factor: 47.728

10.  BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine.

Authors:  D Richman; A S Rosenthal; M Skoog; R J Eckner; T C Chou; J P Sabo; V J Merluzzi
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

View more
  7 in total

Review 1.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

2.  1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity.

Authors:  M Witvrouw; M E Arranz; C Pannecouque; R Declercq; H Jonckheere; J C Schmit; A M Vandamme; J A Diaz; S T Ingate; J Desmyter; R Esnouf; L Van Meervelt; S Vega; J Balzarini; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

3.  A nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitors.

Authors:  M E Goldman; J A O'Brien; T L Ruffing; W A Schleif; V V Sardana; V W Byrnes; J H Condra; J M Hoffman; E A Emini
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

Review 4.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

5.  Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors.

Authors:  V W Byrnes; V V Sardana; W A Schleif; J H Condra; J A Waterbury; J A Wolfgang; W J Long; C L Schneider; A J Schlabach; B S Wolanski
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

6.  Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro.

Authors:  M Baba; S Shigeta; S Yuasa; H Takashima; K Sekiya; M Ubasawa; H Tanaka; T Miyasaka; R T Walker; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

7.  Column-switching high-performance liquid chromatographic determination of a 2-pyridinone-based human immunodeficiency virus type 1 (HIV-1)-specific reverse transcriptase inhibitor in human plasma.

Authors:  E J Woolf; B K Matuszewski
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.